Nyxoah SA key statistics and ratios
In fiscal 2025, Nyxoah SA had return on equity of -116.5%, an operating margin of -833.2%, debt equal to 0.0% of equity and a current ratio of 1.25. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|
| Gross margin | 56.5% | 64.4% | 62.7% | 61.9% | 65.7% | 63.1% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | −833.2% |
| Net margin | <−999% | <−999% | <−999% | −993.8% | <−999% | −899.1% |
| Free-cash-flow margin | <−999% | <−999% | −961.2% | <−999% | <−999% | −696.4% |
| Return on equity | — | −19.4% | −22.2% | −39.4% | −56.8% | −116.5% |
| Return on assets | — | −16.9% | −18.8% | −31.8% | −42.5% | −67.2% |
| Asset turnover | — | 0.01 | 0.02 | 0.03 | 0.03 | 0.07 |
| Current ratio | — | 12.10 | 6.72 | 4.73 | 4.56 | 1.25 |
| Debt to equity | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | n/m | n/m | n/m | n/m | n/m | n/m |
| R&D as % of revenue | >999% | >999% | 514.3% | 612.9% | 759.2% | 427.4% |
| Capital spending as % of revenue | 814.5% | 172.4% | 28.7% | 57.5% | 25.8% | 8.0% |
Financial health
- Short-term assets cover short-term liabilities $72m of assets due within a year against $57m of liabilities due within a year.
- Short-term assets cover long-term liabilities $72m short-term assets against $24m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$94m against $136,805 of interest.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Compare with peers
- Inspiremd, Inc. statistics
- Solana Co statistics
- Nano-x Imaging Ltd. statistics
- Work Medical Technology Group LTD statistics
- Neuroone Medical Technologies Corp statistics
Head to head: NSPR vs NYXHHSDT vs NYXHNNOX vs NYXH
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies